![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Precision medicine
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022
This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022
The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022
In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
February 24, 2022
The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021
The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
September 30, 2021
Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH
July 7, 2021
Recent ECOG-ACRIN trial updates and results
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
April 27, 2021
In this interview, Dr. Peter O'Dwyer urges physicians, sites, and testing laboratories to redouble efforts to locate patients for 12 open arms